Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
29,417,016
-
Share change
-
+775,138
-
Total reported value
-
$428,802,845
-
Put/Call ratio
-
12%
-
Price per share
-
$22.35
-
Number of holders
-
92
-
Value change
-
+$26,463,408
-
Number of buys
-
51
-
Number of sells
-
40
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q1 2018
As of 31 Mar 2018,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
92 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,417,016 shares.
The largest 10 holders included
TRV GP II, LLC, TRV GP III, LLC, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, Partner Fund Management, L.P., Redmile Group, LLC, BlackRock Inc., Pharmstandard International S.A., Casdin Capital, LLC, and VANGUARD GROUP INC.
This page lists
92
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.